SANUWAVE Issued U.S. Patent for a Shock Wave Applicator Construction With Movable Electrode

Print Friendly, PDF & Email

/UCW/ SUWANEE, GA – SANUWAVE Health, Inc. (OTCBB:SNWV) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 9,522,011, titled “Shock Wave Applicator with Movable Electrode” that has an expiration date of July 8, 2030. This patent relates to a new electrohydraulic applicator that has either ellipsoidal, parabolic, or spherical reflectors with their aperture intersecting reflector’s long axis at a non-perpendicular angle and which allows the shock wave-generating electrodes to be adjusted up and down relatively to the focal point.

Due to the discharge of the high voltage away from the focal point (defocused discharge) a “pseudo-focal volume” is produced, where the amount of energy deposited inside tissue is reduced when compared to the normal energy found in the focal volume generated by a discharge in the focal point. This design of the applicator allows the delivery of a broader range of energies during treatment with the same applicator and also an extended focal volume inside the targeted region (increased penetration) due to the combination and overlap of the normal focal volume with the pseudo-focal volume. Furthermore, due to non-perpendicular intersection angle of the reflector’s long axis with its aperture, a reversed reflector (described in detail in SANUWAVE’s patent number 9,161,768) can be used with the movable electrode. In this case, the increased focal volume crosses longitudinally the treatment region instead of transversally (as it happens for existing applicator constructions), which allows the treatment of larger tissue volumes in one position of the applicator for superficial treatments.

Kevin A. Richardson II, SANUWAVE’s Chairman of the Board stated, “At SANUWAVE, our constant goal is to improve the effectiveness of our technology and to produce novel approaches that benefit both patient and physician. Based on this philosophy, this new patent protects a new capability of our proprietary technology that has the potential to be a significant asset for our company in the medical field. The increase in focal volume combined with an improved range of energies that can be delivered for the medical treatment using the same source and reflector geometry, represents two advantages of this applicator, which significantly improve the efficiency of the shock wave treatment.”

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. ( is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit


Millennium Park Capital LLC
Christopher Wynne
[email protected]

SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board
[email protected]

Source: SANUWAVE Health, Inc.

, , ,